We can’t show the full text here under this license. Use the link below to read it at the source.
PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan
Initial patient characteristics in a real-world study of oral semaglutide for adults with type 2 diabetes in Japan
AI simplified
Abstract
A total of 624 participants initiated the study on oral semaglutide for type 2 diabetes.
- The mean age of participants was 64.1 years, with a standard deviation of 14.1 years.
- Participants had a mean body weight of 72.4 kg and a mean body mass index of 27.5 kg/m².
- The median duration of type 2 diabetes among participants was 9.3 years.
- Most participants (75.6%) were already taking glucose-lowering medications at baseline, with metformin being the most common.
- A significant majority (86.0%) had a target for glycemic control of glycated hemoglobin ≤7%.
- Younger participants (<75 years) had a higher mean body mass index compared to older participants (≥75 years), but glycated hemoglobin levels were similar.
AI simplified
Key numbers
64.1 years
Mean Age
Mean age of participants enrolled in the study.
75.6%
Proportion on Glucose-Lowering Medications
Percentage of participants taking glucose-lowering medications at baseline.
27.5 kg/m²
Mean BMI
Mean body mass index of participants at baseline.